Clinical Trial Update: Citalopram for Agitation in Alzheimer's Disease [Phase 3]

View source ↗

Summary

The CitAD Phase 3 trial evaluating citalopram for agitation in Alzheimer's disease has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Citalopram (Citalopram hydrobromide)

Snippet

Sponsor: JHSPH Center for Clinical Trials | Conditions: Alzheimer's Disease, Agitation | Phase 3 | Status: COMPLETED | Results posted: 2014-06-27